Survival improvement of young patients, aged 16-23, with Hodgkin lymphoma (HL) during the last three decades. The prognostic factors, treatments and outcomes of 55 young adults (16-23 years old) with Hodgkin lymphoma (HL) treated in the Second Department of Internal Medicine Propaedeutic, Medical Oncology Unit, Athens University, over the past 25 years, are reviewed. Patients were treated with the chemotherapy regimens available at each time period which were MOPP (Group A 1978-1987), MOPP/ABVD (Group B